APELOA: CDMO business is gradually entering a harvest period and is expected to lead the company's performance into a new growth stage
APELOA stated on the interactive platform that the company's CDMO business has performed better than its active pharmaceutical ingredient (API) business. On one hand, the API business is at the bottom of the industry cycle, facing year-on-year performance pressure; on the other hand, the CDMO business is gradually entering a harvest period, and it is expected to lead the company's performance into a new growth stage
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments